Is sensitivity to cyclosporine influenced by the HLA-DR phenotype of kidney graft recipients?
Kyriakopoulos
G
G
Organ Transplant Unit, University of Thessaloniki, Greece.
Antoniadis
A
A
Gakis
D
D
Papanikolaou
V
V
D001379:Azathioprine / Q000627:therapeutic use; D002102:Cadaver; D016572:Cyclosporine / Q000097:blood / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D006084:Graft Rejection / Q000453:epidemiology / Q000276:immunology*; D006684:HLA-DR Antigens / Q000276:immunology*; D006801:Humans; D016130:Immunophenotyping; D007166:Immunosuppressive Agents / Q000097:blood / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000276:immunology*; D019520:Living Donors; D008775:Methylprednisolone / Q000627:therapeutic use; D012189:Retrospective Studies; D014019:Tissue Donors
D006684:HLA-DR Antigens; D007166:Immunosuppressive Agents; D016572:Cyclosporine; D001379:Azathioprine; D008775:Methylprednisolone